Rigel Pharmaceuticals (RIGL) Free Cash Flow (2010 - 2026)

Rigel Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 405.15% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $79.3 million, a 122.73% increase from a year earlier, with the FY2025 full-year figure at $75.7 million, up 140.4% from the prior year.
• Free Cash Flow declined to $2.7 million in Q1 2026 per RIGL's latest filing, from $22.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $30.5 million in Q2 2025 and bottomed at -$25.9 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$893000.0 (2025), against an average of $1.8 million.
• Across the five-year window, Free Cash Flow sank 123.52% in 2022 and surged 10011.59% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$22.8 million in 2022, then surged by 72.56% to -$6.3 million in 2023, then soared by 331.34% to $14.5 million in 2024, then jumped by 51.55% to $22.0 million in 2025, then slumped by 87.6% to $2.7 million in 2026.
• Per Business Quant, the three latest RIGL Free Cash Flow figures stand at $2.7 million (Q1 2026), $22.0 million (Q4 2025), and $24.0 million (Q3 2025).